标题：浸润性乳腺癌PTEN、p53、EGFR与ER、PR及HER-2表达的关系

      作者：汤永峰 1，冯晓敏 1，谢莉莉 2
    （1.南通体臣卫生学校，江苏 南通 226007；
2.南京市妇幼保健院病理科，江苏 南京 210004）

      卷次： 2014年25卷5期

      【摘要】 目的 研究乳腺癌中雌激素受体(ER)、孕激素受体(PR)、表皮生长因子受体2 (HER-2)与丢失性磷
酸酶-张力蛋白基因(PTEN)、蛋白p53、表皮生长因子受体(EGFR)的关系。方法 采用免疫组织化学S-P法检测
ER、PR、HER-2、PTEN、p53和EGFR在68例乳腺浸润性癌和10例乳腺纤维腺瘤组织标本中的表达。结果 ER、
PR、HER-2、PTEN、p53和EGFR的表达分别是44.1%、47.1%、54.4%、45.6%、51.5%、58.8%，PTEN蛋白表达与ER
呈正相关；p53蛋白表达与ER、PR表达呈负相关；EGFR的表达与ER呈负相关、与HER-2呈正相关。结论 联合
检测ER、PR、HER-2、PTEN、p53、EGFR对临床上乳腺癌患者判断预后和靶向治疗有重要临床意义。

      【关键词】 乳腺癌；雌激素受体（ER）；表皮生长因子受体2；p53；表皮生长因子受体

      【中图分类号】 R737.9 【文献标识码】 A 【文章编号】 1003—6350（2014）05—0630—04


Expression of PTEN, p53, EGFR, ER, PR and HER-2 in invasive breast cancer.
TANG Yong-feng 1, FENG
Xiao-min 1, XIE Li-li 2. 1. Nantong Tichen Health School, Nantong 226007, Jiangsu, CHINA; 2. Department of
Pathology, Nanjing Maternity and Child Health Care Hospital, Nanjing 210004, Jiangsu, CHINA

【Abstract】 Objective To evaluate the expression and significance of estrogen receptor (ER), progesterone
receptor (PR), human epidermal growth factor receptor 2 (HER-2), phosphatase and tensin homolog deleted on chro-
mosome ten (PTEN), protein 53 (p53) and epithelial growth factor receptor (EGFR) in the invasive breast cancer.
Methods S-P immunohistochemistry was used to detect the expression of ER, PR, HER-2, PTEN, p53 and EGFR in
68 cases of breast cancer and 10 cases of breast fibroadenoma. Results The expression rate of ER, PR, HER-2,
PTEN, p53 and EGFR were 44.1%, 47.1%, 54.4%, 45.6%, 51.5% and 58.8%, respectively. The expression of PTEN
was positively correlated with the expression of ER, and the expression of p53 was negatively correlated with the ex-
pression of ER and PR. EGFR expression was negatively correlated with ER expression, while positively correlated
with HER-2 expression. Conclusion The combined detection of ER, PR HER-2, PTEN, p53, EGFR could indicate
the prognosis of breast cancer, which plays an important role in individual treatment.

      【Key words】 Breast cancer; Estrogen receptor (ER); Human epidermal growth factor receptor 2 (HER-2); Pro-
tein 53 (p53); Epithelial growth factor receptor (EGFR)